Categories

Business Ideas
Business Opportunities
Corporate
Home Business
International Business
Management
Online Business
Public Company
Public Relations
Small Business

Popular Articles

generic levitra
Shree Cements Q3 net rises 35% to Rs 167 cr
Shree Cements has reported 35 per cent increase in net profit to Rs 167.4 crore in the third quarter ended December 31, 2009 as against Rs 124 crore in the same qaurter last year.

payday loans canada
RIL in talks with IL&FS on Haryana SEZ
Having acquired contiguous land of over 8,000 acres at Jhajjar in Haryana, Reliance Haryana SEZ Ltd (a joint venture between Reliance Ventures Ltd and Haryana State Infrastructure and Industrial Development Corporation, or HSIIDC) is likely to rope in Infrastructure Leasing & Financial Services Ltd (IL&FS) as a consultant and co-partner in the project.

News of the day

Next stop Karnataka?
The BJP leadership fears the Congress party is likely to try and topple the Yeddyurappa government in Karnataka. With former chief minister and Janata Dal (Secular) leader H D Kumaraswamy knocking at the Congress door, the Karnataka Congress is waiting for the signal from the party high command to begin Operation Topple after the Budget session is over. Part of the plan, it appears, is to put pressure on business houses close to the Yeddyurappa government to distance themselves from the government.
Home Business

Suven Life Sciences granted patents in 9 markets

Suven Life Sciences, a Hyderabad-based biopharmaceutical company specialising in central nervous system (CNS) diseases, on Wednesday said that its clinical candidate for Alzheimer’s disease has secured product patent in India, Mexico, South Africa, Singapore, New Zealand, Korea, Eurasia, Australia and Europe markets. The granted product patent in all these countries is valid till June 2023. - Suven Life Sciences to raise $50 mn via securities - Suven Life gets two more US patents for NCEs - Suven Life"s drug discovery achieves milestone - Suven in talks with global drug makers for licensing deal: CEO - Suven Life hits upper circuit on fund-raising plan - Suven to raise up to $20 mn through equity placement The granted patent for the candidate (SUVN-502), achieved through internal discovery efforts of Suven, has been validated in all the nine member countries of Eurasia (including Russia) and 37 member countries of Europe including major markets like Germany, Switzerland, Denmark, Spain, France, UK, Italy, the Netherlands, Poland, Sweden and Finland, Suven said in a press release. SUVN-502 completed the Phase-I single ascending and multiple ascending studies at Switzerland and demonstrated to be very safe at all doses tested. The company is planning to initiate the clinical Phase-II proof-of-concept studies during 2010 and is targeting launching the product by end of 2013 or early 2014. Development of GlaxoSmithKline’s molecule, which also falls under the same category, is currently in Phase-II, the release added. The scrip of Suven Life is currently trading at Rs 29 on the BSE, up 4.88 per cent as against the previous close of Rs 27.65.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009